课题基金 / 基金详情

Vaccine and Monoclonal Antibody Studies in HIV-infected Subjects

Vaccine and Monoclonal Antibody Studies in HIV-infected Subjects
HIV 感染者的疫苗和单克隆抗体研究
批准号：
8745627
负责人：
Barney Graham
金额：
$53.11万
依托单位：
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/8745627
关键词：
Active immunityAdverse effectsAnti-Retroviral AgentsAntibodiesClinicClinicalClinical ResearchClinical TrialsConduct Clinical TrialsDoseGoalsHIVHIV InfectionsHIV-1Immune responseImmunotherapeutic agentInfectionInfection ControlMedication ManagementMonoclonal AntibodiesPassive ImmunityPhasePreventionRegimenResearch Project GrantsTherapeutic StudiesUnited States National Institutes of HealthVaccinesbasehuman monoclonal antibodiesmethod developmentvaccine candidatevolunteer

项目摘要

项目成果

Barney Graham的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Summary: This clinical research project is for clinical trials related to active immunity (vaccines) and passive immunity (monoclonal antibodies) directed against HIV that are evaluated in HIV-infected volunteers through clinical trials conducted by the VRC Clinic at the NIH Clinical Center. A brief summary of each study to date follows. VRC 101 (06-I-0056) was the first Phase I therapeutic study of two candidate HIV-1 vaccines developed by the VRC and administered in a prime-boost regimen. VRC 601 (13-I-0189) is the first Phase I dose-escalation study in HIV-infected volunteers of a human monoclonal antibody developed by the VRC with broad HIV-1 neutralizing activity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Cellular Immune Responses to RSV infection in Mice
Rapid Development of Vaccines for Emerging Viruses
Factors Contributing To Immune-Enhanced Disease In The Pathogenesis of RSV
Vectors and Methods to Increase Immunogenicity during DNA Vaccination
海外基金